Enanta Pharmaceuticals (ENTA) Retained Earnings (2012 - 2026)
Enanta Pharmaceuticals (ENTA) reported Retained Earnings of -$430.0 million for Q1 2026, down 16.84% on a YoY basis from -$517.1 million in Q1 2025, and down 130586.32% quarter-over-quarter from -$329000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) Retained Earnings (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported Retained Earnings for 15 years, with the latest figure at -$430.0 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 16.84% year-over-year to -$430.0 million; the trailing twelve-month figure through Mar 2026 stood at -$430.0 million (down 16.84% YoY), and the FY2025 full-year result was -$339000.0, up 99.9% from the prior year.
- Retained Earnings for Q1 2026 stood at -$430.0 million, down from -$329000.0 in the prior quarter.
- The five-year high for Retained Earnings was -$329000.0 in Q4 2025, with the low at -$430.0 million in Q1 2026.
- Historically, Retained Earnings has averaged -$131.1 million across 5 years, with a median of -$46.8 million in 2022.
- Annual changes were most pronounced in 2024 — Retained Earnings slumped 64568.54% — and 2025, when it soared 99.9%.
- Enanta Pharmaceuticals' Retained Earnings stood at -$102.2 million in 2022, then surged by 99.48% to -$534000.0 in 2023, then tumbled by 64568.54% to -$345.3 million in 2024, then soared by 99.9% to -$329000.0 in 2025, then slumped by 130586.32% to -$430.0 million in 2026.
- The last three Retained Earnings figures came in at -$430.0 million (Q1 2026), -$329000.0 (Q4 2025), and -$339000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | -429.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -429.96 Mn |
| Dec 31, 2025 | -329,000.00 |
| Sep 30, 2025 | -339,000.00 |
| Jun 30, 2025 | -402,000.00 |
| Mar 31, 2025 | -367.97 Mn |
| Dec 31, 2024 | -345.33 Mn |
| Sep 30, 2024 | -323.04 Mn |
| Jun 30, 2024 | -653,000.00 |
| Mar 31, 2024 | -271.56 Mn |
| Dec 31, 2023 | -534,000.00 |
| Sep 30, 2023 | -1.17 Mn |
| Jun 30, 2023 | -178.89 Mn |
| Mar 31, 2023 | -139.82 Mn |
| Dec 31, 2022 | -102.17 Mn |
| Sep 30, 2022 | -3.72 Mn |
| Jun 30, 2022 | -46.83 Mn |
| Mar 31, 2022 | -15.13 Mn |
| Dec 31, 2021 | 18.46 Mn |
| Sep 30, 2021 | -382,000.00 |
| Jun 30, 2021 | -264,000.00 |